Abstract

Toxic epidermal necrolysis (TEN) is a serious cutaneous adverse reaction with high mortality rate. The severe acute respiratory syndrome-coronavirus-2 virus disease represented a global pandemic known as coronavirus disease-2019 (COVID-19), without exact cure up to date. The usage of immunosuppressive drugs during COVID-19 infection is a major clinical challenge; however, it seems inevitable in rare cases. Here we aimed to report a patient, who was treated concomitantly for TEN and COVID-19 with a good clinical outcome by reviewing the existing literature.

Keywords: Toxic epidermal necrolysis, COVID-19, critical care

References

  1. See S, Mumford JM. Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Pharmacother 2001;35:694-7.
  2. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010;36:152-63.
  3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
  4. Jimenez-Cauhe J, Ortega-Quijano D, de Perosanz-Lobo D, Burgos-Blasco P, Vañó-Galván S, Fernandez-Guarino M, et al. Enanthem in Patients With COVID-19 and Skin Rash. JAMA Dermatol 2020;156:1134-6.
  5. Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin Mol Allergy 2020;18:19.
  6. Emadi SN, Hamzelou S, Saffarian Z, Shakoei S. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report. Dermatol Ther 2021;34:e14656.
  7. Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M. Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). Cureus 2020;12:e8198.
  8. Saha M, D’Cruz A, Paul N, Healy R, Collins D, Charles DA, et al. Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: ‘Killing 2 birds with one stone’. J Eur Acad Dermatol Venereol 2021;35:e97-8.
  9. Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020;19:102559.
  10. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect 2020;80:607-13.
  11. Tzilas V, Manali E, Papiris S, Bouros D. Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool. Respiration 2020;99:1087-9.
  12. Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. Dermatol Ther 2020;33:e13986.

Copyright and license

Copyright © 2021 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite?

1.
Çevik B, Ordu M, Bombacı E, Yakupoğlu S, Saraçoğlu KT. Concurrent Management of a Patient with Toxic Epidermal Necrolysis and Coronavirus Disease-19: A Case Presentation. Turk J Intensive Care. 2021;19(3):141-143. https://doi.org/10.4274/tybd.galenos.2021.43153